Gene expression profiling of tamoxifen-associated uterine cancers: evidence for two molecular classes of endometrial carcinoma
- 29 February 2004
- journal article
- research article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 92 (2), 719-725
- https://doi.org/10.1016/j.ygyno.2003.10.038
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Molecular determinants of tumor differentiation in papillary serous ovarian carcinomaMolecular Carcinogenesis, 2003
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- The secrets of selective estrogen receptor modulation: Cell-specific coregulationCancer Cell, 2002
- Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: a preferential survivin–cyclin B linkLeukemia, 2002
- Risk and prognosis of endometrial cancer after tamoxifen for breast cancerThe Lancet, 2000
- Chapter 3: Endogenous Estrogens as Carcinogens Through Metabolic ActivationJNCI Monographs, 2000
- Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJNCI Journal of the National Cancer Institute, 1998
- Tamoxifen Use in Breast Cancer Patients Who Subsequently Develop Corpus Cancer Is Not Associated with a Higher Incidence of Adverse Histologic FeaturesGynecologic Oncology, 1994
- Endometrial Cancer in Tamoxifen-Treated Breast Cancer Patients: Findings From the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 *JNCI Journal of the National Cancer Institute, 1994
- The epidemiology of endometrial cancerGynecologic Oncology, 1991